SOUTH SAN FRANCISCO, Calif. - Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company, has announced the immediate appointments of Jordyn Tarazi as Vice President, Investor Relations and Corporate Communications, and Nikhil Aneja as Vice President, Finance. The company, which specializes in developing treatments for liver and viral diseases, is reinforcing its leadership as it prepares to release clinical data later in the year.
Executive Vice President and Chief Financial Officer Lesley Ann Calhoun expressed confidence in the new appointees, highlighting the strategic expansion of the team to support Aligos' growth. Tarazi brings a comprehensive background in investor relations and corporate communications from her previous role at ABio-X Holdings - Inc., and earlier as Head of Investor Relations at CohBar, Inc. Her career began in investment banking, assisting companies to raise over $1B.
Aneja joins Aligos with a wealth of finance and accounting leadership experience, having led a global accounting team at CareDx (NASDAQ:CDNA), Inc. His career in life sciences includes roles at Global Blood Therapeutics (NASDAQ:GBT), Inc. and ZS Pharma, Inc. Both Tarazi and Aneja have expressed enthusiasm for their new roles and the company's prospects in advancing its pipeline of therapeutics.
Aligos Therapeutics, founded in 2018, aims to lead in treating liver and viral diseases, focusing on conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical needs, including coronaviruses and chronic hepatitis B (CHB).
The company's forward-looking statements, as per the U.S. Private Securities Litigation Reform Act of 1995, indicate an anticipation of significant clinical data in the later part of the year and confidence in the strategic team growth to enhance Aligos' pipeline development. These statements, however, are subject to risks and uncertainties typical of the drug development process.
This news is based on a press release statement from Aligos Therapeutics. The company has not provided further details on the expected clinical data or the specific responsibilities of the new vice presidents. Investors and stakeholders in the biopharmaceutical sector may look forward to updates on Aligos' progress and its impact on the treatment of liver and viral diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.